Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-103 in Recurrent or Progressive High-grade Glioma
NCT07710690Phase 1Recruiting
- Sponsor
- Neuregen Therapeutics
- Start
- Jul 2026
- Primary completion
- Apr 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NRG-103 in glioma, sponsored by Neuregen Therapeutics. Primary endpoints: Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest at 2 years and Dose-Limiting Toxicities at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
NRG-103
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07710690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710690.